Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated guidelines from the centers for disease control and prevention, national institutes of health, and HIV medicine association of the infectious diseases society of America

Clinical Infectious Diseases

Volumn 58, Issue 9, 2014, Pages 1308-1311

  Masur, Henry ^a   Brooks, John T ^b   Benson, Constance A ^c   Holmes, King K ^d   Pau, Alice K ^a   Kaplan, Jonathan E ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

guideline; HIV AIDS; online; opportunistic infections; revision

Indexed keywords

ANTIVIRUS AGENT;

ADOLESCENT DISEASE; ADULT DISEASE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS RETINITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; TUBERCULOSIS; URBAN AREA; ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COMPLICATION; HIV INFECTIONS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; NATIONAL HEALTH ORGANIZATION; PAPILLOMAVIRUS INFECTIONS; UNITED STATES;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; NATIONAL INSTITUTES OF HEALTH (U.S.); PAPILLOMAVIRUS INFECTIONS; TUBERCULOSIS; UNITED STATES;

EID: 84898850301     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu094     Document Type: Review

References (35)

1. Centers for Disease Control and Prevention. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1989; 38(suppl 5):1-9
2. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. N Engl J Med 1993; 329:898-904
3. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis 1995; 21(suppl 1):S1-11
4. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. US Public Health Services/Infectious Diseases Society of America. Clin Infect Dis 1997; 25(suppl 3):S313-35
5. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep 1999; 48: 1-59. : 61-6
6. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1-52
7. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207; quiz CE1-4
8. National Institutes of Health, AIDSinfo . Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents, 2013. Available at: Www.aidsinfo.nih.gov. Accessed 22 April 2013
9. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-9
10. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60
11. Buchacz K, Baker RK, Palella FJ Jr, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: A cohort study. AIDS 2010; 24:1549-59
12. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34
13. Greenberg AE, Hader SL, Masur H, Young AT, Skillicorn J, Dieffenbach CW. Fighting HIV/AIDS in Washington, D.C. Health Aff (Millwood) 2009; 28:1677-87
14. Mocroft A, Bannister WP, Kirk O, et al. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. Antivir Ther 2012; 17:1291-300
15. Losina E, Freedberg KA. Life expectancy in HIV. BMJ 2011; 343:d6015
16. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-And-Treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793-800
17. Hanna DB, Buchacz K, Gebo KA, et al. Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis 2013; 56:1174-82
18. Hall HI, Espinoza L, Benbow N, Hu YW. Epidemiology of HIV infection in large urban areas in the United States. PLoS One 2010; 5:e12756
19. Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr 2012; 59:368-75
20. Rebeiro P, Althoff KN, Buchacz K, et al. Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr 2013; 62:356-62
21. Althoff KN, Buchacz K, Hall HI, et al. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med 2012; 157:325-35
22. d'Arminio Monforte A, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Int Med 2005; 165:416-23
23. Novak RM, Richardson JT, Buchacz K, et al. Immune reconstitution inflammatory syndrome: Incidence and implications for mortality. AIDS 2012; 26:721-30
24. Marais S, Meintjes G, Pepper DJ, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 2013; 56:450-60
25. Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-Associated cryptococcal meningitis: A prospective study. J Acquir Immune Defic Syndr 2009; 51:130-4
26. Meintjes G, Scriven J, Marais S. Management of the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep 2012; 9:238-50
27. Auld AF, Mbofana F, Shiraishi RW, et al. Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy - Mozambique, 2004-2008. PLoS One 2013; 8:e54665
28. Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005; 40:169-74
29. Lawn SD, Badri M,Wood R. Tuberculosis among HIV-infected patients receiving HAART: Long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-16
30. Maurer T, Ponte M, Leslie K. HIV-Associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357:1352-3
31. Van Rie A,Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: Incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr 2011; 56:349-55
32. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: A 20-year cohort study. AIDS 2009; 23:41-50
33. Deeken JF, Tien-A-Looi A, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012; 55:1228-35
34. Thio CL, Smeaton L, Saulynas M, et al. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS 2013; 27:191-201
35. Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: A systematic review. Sex Transm Infect 2012; 88:558-64.